Harvard psychiatrist highlights ketogenic trials reshaping mental health care

From fringe theory to hospital trials

Chris Palmer has helped turn a once-marginal idea into a serious line of psychiatric research: the possibility that ketones may change the brain’s energy supply enough to affect mood and psychosis. At Harvard Medical School and beyond, he is highlighting a wave of studies at Oxford, Stanford, Mayo Clinic, McLean, and other centers that are no longer asking whether keto is interesting, but whether it can hold up under controlled testing.

That shift matters because the evidence base has moved beyond anecdote. What used to live in patient stories and online keto circles is now being measured in randomized trials, neuroimaging markers, metabolic labs, and symptom scales. The excitement is real, but so is the caution: these studies are designed to test signals, not to replace established psychiatric care overnight.

Why researchers are looking at keto now

Palmer’s case for ketogenic therapy has always been tied to metabolism. McLean Hospital says his clinical and personal journey shaped the work, including a moment in 2017 when he witnessed a patient with schizoaffective disorder transform on a ketogenic diet. By 2022, he was publicly advancing the brain energy theory, arguing that mental disorders may reflect metabolic problems in the brain.

That idea is resonating because it offers a different lens on conditions that can be stubbornly hard to treat. The current studies are not trying to prove that keto is a cure-all. They are testing whether changing fuel availability, insulin signaling, and related pathways can improve symptoms in people whose illnesses have not responded well to conventional treatment.

What the depression trials are showing

Oxford’s DIME study has become one of the clearest symbols of the field’s legitimacy. Described by the NIHR Oxford Health Biomedical Research Centre as the first randomized controlled trial of a ketogenic diet for treatment-resistant depression, it enrolled 100 patients in the United Kingdom between ages 18 and 65 who had already tried at least two antidepressants in the current episode. The intervention used six weeks of prepared ketogenic meals plus weekly dietetic support, with depression and anxiety tracked through week 12.

A separate randomized clinical trial published in JAMA Psychiatry on February 4, 2026, followed 88 UK participants with treatment-resistant depression and found that both the ketogenic and control groups improved rapidly, with greater improvement in the ketogenic arm after six weeks. That detail is important for readers trying to separate hope from hype. It suggests a meaningful signal, but it also shows why the control condition, study structure, and support around the diet matter just as much as the macronutrients themselves.

Where bipolar disorder and psychosis enter the picture

Stanford has already moved from pilot work into the next phase. Stanford Medicine reported in April 2024 that a pilot study of 21 adults with bipolar disorder or schizophrenia and metabolic disorders found the ketogenic diet may help stabilize the brain. Stanford’s later randomized trial record, NCT06748950, is not yet recruiting and is designed to assess quality of life in schizophrenia, bipolar disorder, and major depressive disorder.

McLean Hospital is also pushing forward with a bipolar disorder trial that will enroll 50 participants with early bipolar disorder in an outpatient randomized controlled design. The study is set up to assess neuroimaging markers, energy metabolism, oxidative stress, insulin resistance, and psychotic and mood symptoms. That mix of outcomes shows how seriously researchers are now treating the metabolic angle, not just as a diet question, but as a brain science question.

Dost Öngür, McLean’s chief of psychotic disorders, has said some patients have had far better responses to the ketogenic diet than to medications. That is the kind of statement that gets attention in the keto world, but the trial design tells the rest of the story: researchers are still trying to determine which effects are specific, which are durable, and which may come from the intensity of care that often accompanies a tightly supervised diet.

The trials now expanding the map

Mayo Clinic has entered the field with KETO-MAYO, a recruiting open-label study that began on August 12, 2025. The trial, NCT07121894, plans to enroll 30 adults with bipolar depression, with primary completion estimated for December 31, 2028 and study completion for May 1, 2029. That is a long runway, which is exactly what serious psychiatry research looks like when it is trying to answer a hard question instead of chasing a quick headline.

A 2024 protocol in Frontiers in Nutrition brings even more of the field into view. That randomized placebo-controlled trial involves 100 adults with bipolar disorder, schizoaffective disorder, or schizophrenia over 14 weeks, and it notes that these disorders can reduce life expectancy by up to 25 years. The protocol matters because it shows how the ketogenic conversation has broadened from symptom relief to the bigger burden of severe mental illness, including the physical health costs that often come with it.

Money, momentum, and the new institutional buy-in

Philanthropy has helped push this from curiosity to infrastructure. McLean said Baszucki Group gave a $2 million gift for its bipolar trial, and Baszucki Group announced a £1.17 million grant on May 21, 2026 to support Oxford’s early-psychosis ketogenic therapy trial. In practice, that kind of funding is what allows researchers to build the larger, longer studies needed to move from promising signals to real clinical guidance.

The growing support also reflects how the conversation has changed inside medicine. This is no longer just about whether keto can help someone lose weight or improve blood sugar. The question now being asked in university labs is whether a ketogenic approach can become a credible metabolic tool for conditions that psychiatry has struggled to treat well.

What this does and does not mean for keto readers

For the keto community, the headline is thrilling: elite institutions are now formally testing the diet for depression, bipolar disorder, schizophrenia, schizoaffective disorder, and major depressive disorder. But the sober reading is just as important. A trial can show a signal, a pattern, or a meaningful difference at a specific time point; it cannot, by itself, make keto a universal treatment or erase the need for standard psychiatric care.

That is why the more careful studies matter so much. Prepared meals, weekly dietetic support, control groups, neuroimaging, and long follow-up periods all help answer the same core question: is keto itself doing the work, or is something about the structure around it driving the result? The answer is still unfolding, but the fact that Harvard-linked voices are talking alongside Oxford, Stanford, Mayo, and McLean is its own kind of milestone.

The leap from fringe theory to formal testing is now unmistakable. What began as an outside idea is being handled like a real scientific question, and that alone says the mental health conversation has already changed.